Adherence to combination therapy among ethnic Chinese patients: A cohort study

Hypertension Research

Volumn 33, Issue 5, 2010, Pages 416-421

  Wong, Martin C S ^a   Jiang, Johnny Y ^a   Griffiths, Sian M ^a  

^a and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

Author keywords

Antihypertensive drugs; Associated factors; Chinese; Combination therapy; Discontinuation

Indexed keywords

AMILORIDE PLUS HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS IRBESARTAN; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; HYDROCHLOROTHIAZIDE PLUS TRIAMTERENE;

ADULT; AGE DETERMINATION; AGED; ARTICLE; CARDIOVASCULAR RISK; CAUCASIAN; CHINESE; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; HEALTH SERVICE; HONG KONG; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRESCRIPTION; PRIMARY MEDICAL CARE; RESIDENTIAL HOME; SENSITIVITY ANALYSIS; SEX DETERMINATION; SOCIOECONOMICS;

ADULT; AGE FACTORS; AGED; ANTIHYPERTENSIVE AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; DATABASES, FACTUAL; DRUG THERAPY, COMBINATION; FEMALE; HONG KONG; HUMANS; HYPERTENSION; MALE; MEDICATION ADHERENCE; MIDDLE AGED; ODDS RATIO; REGRESSION ANALYSIS; REMINDER SYSTEMS; SEX FACTORS;

EID: 77951939876     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2009.229     Document Type: Article

References (47)

1. Psaty BM, Lumsley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, Weiss NS. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003; 289: 2534-2544.
2. McCombs JS, Nichol MB, Newman CM, Sclar DA. The costs of interrupting antihy-pertensive drug therapy in a Medicaid population. Med Care 1994; 32: 214-226.
3. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005; 43: 521-530.
4. Rizzo JA, Simons WR. Variations in compliance among hypertensive patients by drug class: implications for health care costs. Clin Ther 1997; 19: 1446-1457.
5. Caro JJ, Speckman JL. Existing treatment strategies: does noncompliance make a difference? J Hypertens 1998; 12: S533-S537.
6. Mazzaglia G, Ambrosioni E, Alacqua M, Filippi A, Sessa E, Immordino V, Borghi C, Brignoli O, Caputi AP, Cricelli C, Mantovani LG. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation 2009; 120: 1598-1605.
7. Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW, Joffres M, Kastarinen M, Poulter N, Primatesta P, Rodŕguez-Artalejo F, Stegmayr B, Thamm M, Tuomilehto J, Vanuzzo D, Vescio F. Hypertension prevalence and blood pressure levels in 6 European countries, Canada and the United States. JAMA 2003; 289: 2363-2369.
8. Wetzels GE, Nelemans P, Schouten JS, Prins MH. Facts and fiction of poor compliance as a cause of inadequate blood pressure control: a systematic review. J Hypertens 2004; 22: 1849-1855.
9. Sica DA. Rationale for fixed-dose combination in the treatment of hypertension: the cycle repeats. Drugs 2002; 62: 443-462.
10. Brixner DI, Jackson II KC, Sheng X, Nelson RE, Keskinasian A. Assessment of adherence, persistence, and costs among valsartan and hydrochlorothiazide: retrospective cohorts in free-and fixed-dose combinations. Curr Med Res Opin 2008; 24: 2597-2607.
11. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003; 326: 1427-1434.
12. Van Wijk BL, Klungel OH, Heerdink ER, de Boer A. Rate and determinants of 10-year persistence with antihypertensive drugs. J Hypertens 2005; 23: 2101-2107.
13. Perreault S, Lamarre D, Blais L, Dragomir A, Berbiche D, Lalonde L, Laurier C, St-Maurice F, Collin J. Persistence with treatment in newly treated middle-aged patients with essential hypertension. Ann Pharmacother 2005; 39: 1401-1408.
14. World Health Organization. Country Health Information Profiles. Available at: http://www.wpro.who.int/NR/rdonlyres/E3A15481-80E2-400B-B801-B52AC6F0C790/ 0/9finalCHNpro09.pdf. Accessed on 11 December 2009.
15. Ogedegbe G, Mancuso CA, Allegrante JP, Charlson ME. Development and evaluation of a medication adherence self-efficacy scale in hypertensive African-American patients. J Clin Epidemiol 2003; 56: 520-529.
16. Ogedegbe G, Harrison M, Robbins L, Mancuso CA, Allegrante JP. Barriers and facilitators of medication adherence in hypertensive African Americans: a qualitative study. Ethn Dis 2004; 14: 3-12.
17. van Wijk BLG, Shrank WH, Klungel OH, Schneeweiss S, Brookhart MA, Avorn J. A cross-national study of the persistence of antihypertensive medication use in the elderly. J Hypertensi 2008; 26: 145-153. (Pubitemid 350294860)
18. Wong MCS, Jiang JY, Lam A, Fung H, Griffiths S, Mercer SW. Patterns of antihyperten-sive prescribing, discontinuation and switching among a Hong Kong Chinese population from over one million prescriptions. J Hum Hypertens 2008; 22: 714-716.
19. Wong MCS, Jiang JY, Gibbs T, Griffiths SM. Factors associated with antihypertensive drug discontinuation among Chinese patients: a cohort study. Am J Hypertens 2009; 22: 802-810.
20. Caro JJ, Salas M, Speckman JL, Raggio G, Jackson JD. Persistence with treatment for hypertension in actual practice. CMAJ 1999; 160: 31-37.
21. Degli Eposti L, Degli Eposti E, Valpiani G, Di Martino M, Saragoni S, Buda S, Baio G, Capone A, Sturani A. A retrospective, population-based analysis of persistence with antihypertensive drug therapy in primary care practice in Italy. Clin Ther 2002; 24: 1347-1357.
22. Billups SJ, Malone DC, Carter BL. The relationship between drug therapy non-compliance and patient characteristics, health-related quality of life, and health care costs. Pharmacotherapy 2000; 20: 941-949.
23. Vaur L, Vaisse B, Genes N, Elkik F, Legrand C, Poggi L. Use of electronic pill boxes to assess risk of poor treatment compliance: results of a large-scale trial. Am J Hypertens 1999; 12: 374-380.
24. Flack JM, Novikov SV, Ferrario CM. Benefits of adherence to antihypertensive drug therapy. Eur Heart J 1996; 17: 16-20.
25. Knight EL, Bohn RL, Wang PS, Glynn RJ, Mogun H, Avorn J. Predictors of uncontrolled hypertension in ambulatory patients. Hypertension 2001; 38: 809-814.
26. HA and clinical research. Support, Output and Direction. Available at http://www.ha.org.hk/ho/research-ethics/msdc-p181.pdf. Accessed on 04 December 2009.
27. Wong MCS, Jiang JY, Tang JL, Lam A, Fung H, Mercer SW. Health services research in the public healthcare system in Hong Kong: an analysis of over 1 million antihyperten-sive prescriptions between 2004-2007 as an example of the potential and pitfalls of using routinely collected electronic patient data. BMC Health Ser Res 2008; 8: 138. Available at: http://www.ncbi.nlm.nih.gov/pmc/ articles/PMC2453117/pdf/1472-6963-8-138.pdf. Accessed on 04 Dec 2009.
28. Population by-census, 2006. Hong Kong Special Administrative Region, China., Available at: http://www.bycensus2006.gov.hk/en/data/data3/index.htm. Accessed on 04 December 2009.
29. Burke TA, Sturkenboom MC, Lu S, Wenworth CE, Lin Y, Rhoads GG. Discontinuation of antihypertensive drugs among newly diagnosed hypertensive patients in UK general practice. J Hypertens 2006; 24: 1193-1200.
30. Mazzaglia G, Mantovani LG, Sturkenboom MCJM, Filippi A, Trifiro G, Cricelli C, Brignoli O, Caputi AP. Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care. J Hypertens 2005; 23: 2093-2100.
31. Jones JK, Gorkin L, Lian JF, Staffa JA, Fletcher AP. Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: a study of United Kingdom population. BMJ 1995; 311: 293-295.
32. Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther 1998; 20: 671-681.
33. Bourgault C, Senecal M, Brisson M, Marentette MA, Gregoire J-P. Persistence and discontinuation patterns of antihypertensive therapy among newly treated patients: a population-based study. J Hum Hypertens 2005; 19: 607-613.
34. Caro JJ, Speckman JL, Salas M, Raggio G, Jackson JD. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. Can Med Assoc J 1999; 160: 41-46.
35. Degli Esposti L, Degli Esposti E, Valpiani G, Di Martino M, Saragoni S, Buda S, Baio G, Capone A, Sturani A. A retrospective, population-based analysis of persistence with antihypertensive drug therapy in primary care practice in Italy. Clin Ther 2002; 24: 1347-1357.
36. Degli Esposti E, Sturani A, Di Martino M, Falasca P, Novi MV, Baio G, Buda S, Volpe M. Long-term persistence with antihypertensive drugs in new patients. J Hum Hypertens 2002; 16: 439-444.
37. Conlin PR, Gerth WC, Fox J, Roehm JB, Boccuzzi SJ. Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other antihypertensive drug classes. Clin Ther 2001; 23: 1999-2010.
38. Hasford J, Mimran A, Simons WR. A population-based European cohort study of persistence in newly diagnosed hypertensive patients. J Hum Hypertens 2002; 16: 569-575.
39. Erkins JA, Panneman MM, Klungel OH, van den Boom G, Prescott MF, Herings RM. Differences in antihypertensive drug persistence associated with drug class and gender: a PHARMO study. Pharmacoepidemiol Drug Saf 2005; 14: 795-803.
40. Van Wijk BLG, Klungel OH, Heerdink ER, de Boer A. Rate and determinants of 10-year persistence with antihypertensive drugs. J Hypertens 2005; 23: 2101-2107.
41. Woodham RM, Oparil S. Fixed low-dose antihypertensive therapy. In: Lip GYH, Hall JE (eds). Comprehensive Hypertension. Mosby, Philadelphia, 2007, 1061-1073.
42. Halpern MT, Khan ZM, Schmier JK, Burnier M, Caro JJ, Cramer J, Daley WL, Gurwitz J, Hollenberg NK. Recommendations for evaluating compliance and persistence with hypertension therapy using retrospective data. Hypertension 2006; 47: 1039-1048.
43. Grymonpre RE, Didur CD, Montgomery PR, Sitar DS. Pill count, self-report, and pharmacy claims data to measure medication adherence in the elderly. Ann Pharmac-other 1998; 32: 749-754.
44. Chang S, Chan WH, Kong Y, Chan GM, Raymond K, Lee A, Lee SC, Critchley JA, Chan JC. Use of indapamide in hospital and community clinics and its effect on plasma potassium in Chinese patients. J Clin Pharm Ther 1998; 23: 295-302.
45. Yuen YH, Chang S, Chong CK, Lee SC, Critchley JA, Chan JC. Drug utilization in a hospital general medical outpatient clinic with particular reference to antihypertensive and antidiabetic drugs. J Clin Pharm Ther 1998; 23: 287-294.
46. Cheung BM, Wong YL, Lau CP. Queen Mary Utilization of Antihypertensive Drugs Study: use of antihypertensive drug classes in the hypertension clinic 1996-2004. Br J Clin Pharmacol 2005; 60: 90-97.
47. Carter BL. Adherence, quality of life, cost effectiveness, and the role of the pharmacist. In: Lip GYH, Hall JE (eds). Comprehensive Hypertension. Mosby, Philadelphia, 2007, 1119-1127.